Trump said you could learn something from this man

Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement.

John Jacobs Biography and Net Worth

CEO of Harmony Biosciences

Mr. Jacobs is President and Chief Executive Officer for Harmony Biosciences.

He joined Harmony from Teva Pharmaceuticals, where he held leadership roles as Senior Vice President and General Manager of the Respiratory Business Unit, Senior Vice President of Commercial Operations in North America and General Manager of Teva in Canada. Prior to joining Teva, he held positions of increasing scope and responsibility at major pharmaceutical companies, including Cephalon, Wyeth and Pfizer. Mr. Jacobs has over 25 years of commercial experience across multiple therapeutic areas, including CNS, Sleep Disorders, Pain Care and Respiratory, as well as rare disease and other specialty markets. His demonstrated expertise in developing market-leading commercial strategies, major product launches and building and leading highly effective teams and organizations has helped to shape Harmony’s positive culture of compassion for patients and passion for our business.

He holds a bachelor’s degree in business and a Master of Business Administration in marketing from the State University of New York.

How do I contact John C. Jacobs?: The corporate mailing address for Mr. Jacobs and other Harmony Biosciences executives is 630 W GERMANTOWN PIKE SUITE 215, PLYMOUTH MEETING PA, 19462. Harmony Biosciences can also be reached via phone at 484-539-9800 and via email at [email protected]. Learn More on John C. Jacobs' contact information.
Has John C. Jacobs been buying or selling shares of Harmony Biosciences?: John C. Jacobs has not been actively trading shares of Harmony Biosciences during the last ninety days. Most recently, John C. Jacobs sold 40,000 shares of the business's stock in a transaction on Monday, August 15th. The shares were sold at an average price of $51.07, for a transaction totalling $2,042,800.00. Learn More on John C. Jacobs' trading history.
Who are Harmony Biosciences' active insiders?: Harmony Biosciences' insider roster includes Jeffrey Dayno (Insider), Jeffrey Dierks (Insider), John Jacobs (CEO), and Andreas Wicki (Director). Learn More on Harmony Biosciences' active insiders.
Are insiders buying or selling shares of Harmony Biosciences?: In the last year, insiders at the sold shares 4 times. They sold a total of 33,869 shares worth more than $1,267,489.12. The most recent insider tranaction occured on October, 29th when insider Jeffrey Dierks sold 21,496 shares worth more than $869,943.12. Insiders at Harmony Biosciences own 30.8% of the company. Learn More about insider trades at Harmony Biosciences.
Information on this page was last updated on 10/29/2024.

John C. Jacobs Insider Trading History at Harmony Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/15/2022	Sell	40,000	$51.07	$2,042,800.00
6/15/2022	Sell	15,000	$45.42	$681,300.00
6/13/2022	Sell	25,000	$44.18	$1,104,500.00
3/16/2022	Sell	15,000	$45.32	$679,800.00
12/27/2021	Sell	1,300	$45.03	$58,539.00
12/13/2021	Sell	25,000	$38.22	$955,500.00
9/13/2021	Sell	25,000	$35.93	$898,250.00

John C. Jacobs Buying and Selling Activity at Harmony Biosciences

Harmony Biosciences Company Overview

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Today's Range

Now: $33.01

$32.85

$33.01

50 Day Range

MA: $35.71

$32.13

$41.49

2 Week Range

Now: $33.01

$27.97

$41.61

Volume

8,074 shs

Average Volume

476,782 shs

Market Capitalization

$1.88 billion

P/E Ratio

15.64

Dividend Yield

N/A

Beta

0.77